O03Apremilast, an Oral Phosphodiesterase-4 Inhibitor, is Associated with Long-Term (104-Week) Improvements in Enthesitis and Dactylitis in Patients with Psoriatic Arthritis: Pooled Results from Three Phase III Randomized Controlled Trials

O03Apremilast, an Oral Phosphodiesterase-4 Inhibitor, is Associated with Long-Term (104-Week) Improvements in Enthesitis and Dactylitis in Patients with Psoriatic Arthritis: Pooled Results from Three Phase III Randomized Controlled Trials

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Rheumatology (Oxford, England) England), 2016-04, Vol.55 (suppl_1), p.i33-i34
Hauptverfasser: Gladman, Dafna D, Kavanaugh, Arthur, Adebajo, Adewale O, Gomez-Reino, Juan J, Wollenhaupt, Juergen, Cutolo, Maurizio, Schett, Georg, Lespessailles, Eric, McIlraith, Melissa, Hu, ChiaChi, Edwards, Christopher J, Birbara, Charles A, Mease, Philip J
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:
ISSN:1462-0324
1462-0332
DOI:10.1093/rheumatology/kew122.002